Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Shares of Eli Lilly & Co. LLY slipped 1.88% to $906.18 Tuesday, on what proved to be an all-around mixed trading session for ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We recently compiled a list of the 7 Best Big Company Stocks to Buy Now. In this article, we are going to take a look at ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from TD Cowen maintained a Buy rating on the stock and ...

Sept 5 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on ...

U.S. drugmaker Eli Lilly has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on Thursday. WHY IT'S IMPORTANT Major drugmakers ...

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...

Eli Lilly Partners With AI-Focused Genetic Leap to Develop RNA-Based Drugs (Reuters) -U.S. drugmaker Eli Lilly has signed a research deal with privately held AI-focused firm Genetic Leap to ...

Sept 3 (Reuters) - BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly (LLY.N), opens new tab, filed for an initial public offering in the United States on ...

The primary cause for the selloff could be because Eli Lilly (NYSE:LLY) has cut the knees out from under Hims & Hers biggest selling point: selling weight-loss drugs at a steep discount.